Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
2121-2140 of 3,900 trials

IKS03 for Advanced B Cell Non-Hodgkin Lymphoma

We are studying the effects of IKS03 in patients with advanced B cell non-Hodgkin lymphoma. The goal is to see if it can improve treatment outcomes compared to standard therapies.

Advanced B cell Non-Hodgkin Lymphoma>2 yearsSafety phase (I)Oncology

Advanced Cancer: JK06 Antibody Drug

We are testing a new drug called JK06 for patients with advanced cancer that cannot be removed by surgery. The study aims to evaluate its safety and how well it may work in treating this type of cancer.

Unresectable, Locally Advanced or Metastatic CancerSafety phase (I)Efficacy phase (II)No PlaceboOncology

Soft Tissue Sarcomas: INT230-6 Treatment Study

We are investigating a new treatment for adults with advanced soft tissue sarcomas to see if it works better than standard care. The study will also look at side effects and quality of life for participants.

Myxoid LiposarcomaDedifferentiated LiposarcomaRound Cell Liposarcoma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Gastrointestinal Cancers: Patritumab Deruxtecan Study

We are evaluating a new treatment for people with gastrointestinal cancers to see if it is safe and effective. This study aims to understand how well it works compared to existing options.

Colorectal CancerHepatocellular CarcinomaBiliary Tract Cancer>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsInvestigational MedicinesOncology

Organ Transplantation: Custodiol-N vs. Custodiol Solution

We are studying a new preservation solution for kidney, liver, and pancreas transplants to see if it works as well as the current standard. This research may help improve outcomes for transplant recipients.

Organ Transplant Candidates>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesEndocrinologyHepatologyInternal MedicineNephrologyOrthopedics and Traumatology

Buprenorphine for Severe Suicidal Thoughts in Major Depression

We are studying whether buprenorphine can help reduce severe suicidal ideas in individuals with major depressive episodes. The trial will compare different doses to find the most effective and safest option.

Clinical Depression≤3 monthsEfficacy phase (II)6-10 visitsStandard MedicinesPsychiatry

Psoriatic Arthritis: Guselkumab for Enthesitis

We are studying whether Guselkumab can help reduce inflammation in patients with psoriatic arthritis who have not received prior treatments. This trial focuses on those with ultrasound-confirmed enthesitis.

Psoriatic Arthritis1-2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesRheumatology

Bevacizumab vs. Corticosteroids for Cerebral Radiation Necrosis

We are studying whether bevacizumab is more effective than corticosteroids for treating symptoms of cerebral radiation necrosis in patients with high-grade glioma or brain metastases. The trial also looks at quality of life and other health impacts.

Brain MetastasesHigh-Grade Glioma>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyOncology

ANCA Vasculitis: Stopping Immunosuppressive Therapy

We are studying whether stopping immunosuppressive therapy helps patients with ANCA vasculitis and end-stage renal disease avoid serious health issues compared to continuing treatment.

End-stage Renal DiseaseANCA Vasculitis>2 yearsConfirmation phase (III)Monitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesNephrologyRheumatology

Chronic Depression: Ketamine Treatment Study

We are investigating whether adding ketamine to a therapy for chronic depression can reduce symptoms more effectively than a placebo. This study aims to help improve treatment options for those struggling with depression.

Chronic Depression≤3 monthsEfficacy phase (II)Standard MedicinesPsychiatry

CRISPR CAR Therapy for Blood and Solid Cancers

We are studying the long-term safety and effectiveness of CRISPR CAR cellular therapies in patients with hematological and solid malignancies. This research aims to provide insights into how well this treatment works over time.

Solid TumorsHematologic Malignancies>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesHematologyOncology

Cardiovascular Disease: Low Dose Rivaroxaban in Advanced CKD

We are studying whether a low dose of rivaroxaban can help reduce serious heart-related events in people with advanced chronic kidney disease or on dialysis. This trial compares the medication to a placebo to see if it offers any benefits.

Heart and Kidney Disease>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementCardiologyNephrology

Pancreatic Cancer: New Electroporation Treatments

We are studying the effects of three innovative treatments for pancreatic cancer to see if they improve quality of life and survival. This includes assessing pain levels and weight loss in patients.

Unresectable Pancreatic Cancer>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Liver Cancer: Hyperpolarized Pyruvate MRI Study

We are exploring whether a new MRI technique can help detect small liver tumors earlier in people at risk for hepatocellular carcinoma. This may improve early diagnosis and treatment options.

Primary Liver Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHepatologyInternal Medicine

Chronic Kidney Disease: Ultra-Sensitive MRI Study

We are investigating how advanced MRI can detect metabolic changes in patients with chronic kidney disease and polycystic kidney disease. This research may help improve diagnosis and treatment monitoring.

Autosomal Dominant Polycystic Kidney Disease (ADPKD)Chronic Kidney Disease>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineNephrology

Glioblastoma: Dendritic Cell Vaccine Study

We are testing a personalized vaccine made from your own immune cells and tumor tissue for patients with glioblastoma. The study aims to see if this treatment can improve safety and help patients live longer without disease progression.

Glioblastoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurologyOncology

Depression: Pramipexole for Anhedonia Symptoms

We are studying whether pramipexole can help reduce anhedonia symptoms in people with depression. The trial will also look at its effects on overall mood, physical activity, and sleep quality.

AnhedoniaMajor DepressionConfirmation phase (III)Standard MedicinesPsychiatry

Plaque Psoriasis: TAK-279 Oral Medication

We are studying a new daily oral treatment for people with moderate-to-severe plaque psoriasis. The trial will help us understand its long-term safety and effectiveness.

Plaque Psoriasis>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementDermatology

Plaque Psoriasis: Zasocitinib vs. Deucravacitinib

We are studying whether a new oral medication, zasocitinib, is more effective than deucravacitinib for treating moderate-to-severe plaque psoriasis. The trial will also assess the safety and tolerability of both treatments.

Plaque Psoriasis6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementDermatology

Cochlear Implant Surgery: Testing VSF1.01 Treatment

We are investigating the safety of a new treatment for patients receiving cochlear implants. This study aims to see if it can reduce surgery-related trauma and improve hearing outcomes.

Hearing Loss1-2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboOtolaryngology